Supply chain challenges and issues facing the autologous cell manufacturing industry

We discuss three supply chain challenges and issues facing the autologous cell manufacturing industry that may impact patient outcome and supply chain performance in a commercial setting. These are (i) the potential value of giving priority to the sickest patients with respect to the start of manufacturing their therapy, (ii) determining the optimal manufacturing capacity and reagent replenishment policy for a single cell manufacturing facility, given demand forecasts and patient service levels, and (iii) the resilience of reconfigurable supply chain networks for supply chains with geographically distributed manufacturing capacity.

Please enter your email to access content Read now